Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.Toxins (Basel). 2013; 5: 336-362
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer Cell. 2005; 7: 387-397
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Nature. 2005; 434: 1144-1148
- A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med. 2005; 352: 1779-1790
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet. 2005; 365: 1054-1061
- Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.N Engl J Med. 2013; 369: 2391-2405
- Somatic mutations of calreticulin in myeloproliferative neoplasms.N Engl J Med. 2013; 369: 2379-2390
- MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.PLoS Med. 2006; 3: e270
- MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.Blood. 2006; 108: 3472-3476
- MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.Blood. 2008; 112: 141-149
- Autoimmunity and the risk of myeloproliferative neoplasms.Haematologica. 2010; 95: 1216-1220
- Community-acquired infections and their association with myeloid malignancies.Cancer Epidemiol. 2014; 38: 56-61
- Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study.Cancer Med. 2018; 7: 5796-5802
- Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms.Hemasphere. 2020; 4: e327
- Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study.Br J Cancer. 2013; 108: 2390-2398
- Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.Int J Cancer. 2014; 134: 1741-1750
- Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.Blood. 2018; 132: 973-976
- Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.Nat Cell Biol. 2020; 22: 716-727
- The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity.Leukemia. 2018; 32: 2266-2270
- Longitudinal cytokine profiling identifies GRO-α and EGF as potential biomarkers of disease progression in essential thrombocythemia.Hemasphere. 2020; 4: e371
- Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms.J Cell Mol Med. 2018; https://doi.org/10.1111/jcmm.13753
- Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.Am J Hematol. 2012; 87: 1003-1005
- Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications.Exp Hematol. 2014; 42: 360-368
- Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.Cytokine. 2002; 20: 178-183
- Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.Oncogene. 2011; 30: 990-1001
- Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia.Cell Immunol. 2012; 278: 91-94
- Global cytokine analysis in myeloproliferative disorders.Leuk Res. 2007; 31: 1389-1392
- Evaluation of interleukin-17 serum levels in patients with chronic myeloproliferative diseases.Tumori. 2009; 95: 404-405
- Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.Hematol Transfus Cell Ther. 2018; 40: 120-131
- Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.J Clin Oncol. 2011; 29: 1356-1363
- Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders.Eur J Haematol. 1999; 63: 19-25
- Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.Br J Haematol. 2005; 130: 709-715
- TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.Blood. 2011; 118: 6392-6398
- JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.Blood. 2014; 124: 2996-3006
- Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.Blood. 2015; 126: 972-982
- Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.Nature. 2014; 512: 78-81
- Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets.Mol Cell. 2020; 78: 477-492.e8
- Somatic mutations and cell identity linked by genotyping of transcriptomes.Nature. 2019; 571: 355-360
- Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.Blood. 2007; 110: 986-993
- Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.Cell Stem Cell. 2013; 13: 285-299
- Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis.Cancer Res. 2015; 75: 4753-4765
- Gli1 + Mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target.Cell Stem Cell. 2017; 20: 785-800.e8
- Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.Nat Cell Biol. 2017; 19: 677-688
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling.Leukemia. 2019; 33: 1978-1995
- Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.Blood Adv. 2019; 3: 122-131
- JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Cancer Discov. 2015; 5: 316-331
- Extracellular DNA traps promote thrombosis.Proc Natl Acad Sci U S A. 2010; 107: 15880-15885
- Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.Blood. 2000; 96: 4261-4266
- Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.Sci Transl Med. 2018; 10: 436
- N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.Blood Adv. 2020; 4: 312-321
- Platelets as mediators of thromboinflammation in chronic myeloproliferative neoplasms.Front Immunol. 2019; 10: 1373
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.Haematologica. 2011; 96: 315-318
- Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.Exp Hematol. 2005; 33: 523-530
- Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.Am J Hematol. 2009; 84: 102-108
- Circulating platelets as mediators of immunity, inflammation, and thrombosis.Circ Res. 2018; 122: 337-351
- Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.J Exp Med. 2016; 213: 1723-1740
Article info
Publication history
Published online: December 09, 2020
Footnotes
Financial Support: This research was supported by funds from the Tobacco-Related Disease Research Program of the University of California, Grant Numbers T29FT0267 (G. Ramanathan) and T29IP0414 (A.G. Fleischman). G. Ramanathan was supported by the NCI T32CA009054.
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
